Supplemental Table 1 Summary of Clinical Studies Included in the Population Pharmacokinetic Dataset

ClinicalTrials.gov Identifier	Study Design	Population	Treatment	Planned Sample Size
NCT01012895 https://clinicaltrials.gov/ct2/show/NCT01012895?term=AI447-011&rank=1	Parallel, Open-Label, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-790052 and BMS-650032 (tablet formulation) in Combination in Null Responders to Standard of Care Infected with Chronic Hepatitis C Virus Genotype 1	Males and females 18 to 70 years of age with genotype 1 chronic HCV infection and HCV RNA > 100,000 IU/mL without cirrhosis who are null-responders	Treatment A (DUAL) Sentinel: BMS-790052 60mg QD for up to 24 weeks, and BMS-650032 600mg BID first, then reduced on September 21, 2010 to 200mg BID for a total of up to 24 weeks Treatment A Expansion (DUAL): BMS-790052 60mg QD and BMS-650032 200mg QD or BID for up to 24 weeks Treatment B1, B2 (QUAD) Sentinel: BMS-790052 60mg QD for up to 24 weeks, and BMS-650032 600mg BID first, then reduced on September 21, 2010 to 200mg BID for a total of up to 24 weeks, with Peginterferon-alfa (QW)/ribavirin (BID) for up to 24 weeks Treatment B1, B2 Expansion (QUAD): BMS-790052 60mg QD and BMS-650032 200mg QD or BID, with Peginterferon-alfa (QW)/ribavirin (BID) for up to 24 weeks Treatment B3 (Triple): BMS-790052 60mg QD and BMS-650032 200mg BID, with ribavirin (BID) for up to 24 weeks	10 per sentinel group. 20 per expansion group (A1, A2, B1, B2, B3)

ClinicalTrials.gov Identifier	Study Design	Population	Treatment	Planned Sample Size
NCT01030432 https://clinicaltrials.gov/ct2/show/NCT01030432?term=AI447-016&rank=1	A Phase2a/2b Study of BMS-650032 (tablet formulation) in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection	Males and females 18 to 70 years of age with chronic HCV genotype 1 and genotype 4 without cirrhosis who have not received prior anti-HCV treatment with pegIFN and RBV or other agents with anti-HCV activity (treatment naive). Subjects with decompensated cirrhosis may be included in Stage 2.	Stage 1: BMS-650032 0, 200mg BID, 600mg BID, 600mg QD (1:1:1:1) first, then reduced to 0, 200mg BID (1:3), with Peginterferon-alfa (QW)/ribavirin (BID) for 48 weeks Stage 2: BMS-650032 0, 200mg BID (1:3) for 12 or 24 weeks, with Peginterferon-alfa (QW)/ribavirin (BID) for 24 or 48 weeks	40 (Null-responder: 20, SOC ineligible naïve/intolerant: 20)
NCT01051414 https://clinicaltrials.gov/ct2/show/NCT01051414?term=AI447-017&rank=1	Open label, Phase 2a, BMS-790052 and BMS-650032 (tablet formulation) in Combination Therapy with Japanese Subjects with Genotype 1 Chronic Hepatitis C (HCV) virus Infection	Males and females 20 to 75 years of age with genotype 1 chronic HCV infection without cirrhosis who are null-responder or SOC ineligible naïve/intolerant	BMS-790052 60 mg Q24h, BMS-650032 600mg Q12h up to Week 12, changed to 200mg Q12h between Weeks 12 and 24, for 24 weeks. If prior null-responder does not respond to treatment, BMS-790052 60mg Q24h, BMS-650032 600mg Q12h, with Peginterferon-alfa (QW)/ribavirin (BID) for additional 48 weeks	40 (Null-responder: 20, SOC ineligible naïve/intolerant: 20)

ClinicalTrials.gov Identifier	Study Design	Population	Treatment	Planned Sample Size
NCT01497834 https://clinicaltrials.gov/ct2/show/NCT01497834?term=AI447-026&rank=1	A Phase 3 Japanese Study of BMS-790052 plus BMS-650032 (softgel formulation) Combination Therapy in Chronic Hepatitis C Genotype 1b Infected Subjects Who are Non Response to Interferon plus Ribavirin and Interferon Based Therapy Ineligible naive/intolerant	Males and females 20 to 75 years of age with genotype 1b chronic HCV infection who are non-responders to alfa/RBV or beta/RBV, and IFN based therapy ineligible naive/intolerant subjects	BMS-790052 60 mg Q24h, BMS-650032 100mg Q12h, for 24 weeks. If prior null-responder does not respond to treatment, BMS-790052 60mg Q24h, BMS-650032 600mg Q12h, with Peginterferon-alfa (QW)/ribavirin (BID) for additional 24 weeks	200 (80 prior non-responders, 120 ineligible naive/intolerant)
NCT01581203 https://clinicaltrials.gov/ct2/show/NCT01581203?term=AI447-028&rank=2	A Phase 3 Study with Asunaprevir (softgel formulation) and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects with Chronic Hepatitis C Genotype 1b Infection	Males and females ≥ 18 years of age with genotype 1b chronic HCV infection and HCV RNA > 10,000 IU/mL who are null or partial responders, treatment-naive, or intolerant to or ineligible for Peg/RBV	BMS-790052 60 mg Q24h, BMS-650032 100mg Q12h, for 24 weeks. If does not respond to treatment, BMS-790052 60mg Q24h, BMS-650032 600mg Q12h, with Peginterferon-alfa (QW)/ribavirin (BID) for additional 24 weeks	725